Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a significant advancement for obesity loss . Initial human trials https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost